Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Executive Summary
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.
You may also be interested in...
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.